We identified potentially targetable aberrations including gene fusions in NTRK2 and FGFR3‐TACC3, mutations and/or SCNA's in H3F3A, EGFR, CDK4/6, IDH, NF1, and FGFR3. NTRK fusions are rare and have only been detected in 0.3% of cancers with a higher prevalence in GBM of 1.4% [63]. This evidence concerns the gene NF1 and glioblastoma.